Cart
sales@molnova.com
E7046
CAS No. 1369489-71-3
E7046( —— )
Catalog No. M21835 CAS No. 1369489-71-3
E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM. E7046 exhibits anti-tumor activities.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 56 | In Stock |
|
| 10MG | 79 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameE7046
-
NoteResearch use only, not for human use.
-
Brief DescriptionE7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM. E7046 exhibits anti-tumor activities.
-
DescriptionE7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM. E7046 exhibits anti-tumor activities.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1369489-71-3
-
Formula Weight483.39
-
Molecular FormulaC??H??F?N?O?
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL (206.87 mM)
-
SMILESO=C(O)C1=CC=C([C@@H](NC(C2=C(OC3=CC=CC(C(F)(F)F)=C3)N(C)N=C2C(F)F)=O)C)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. X. Bao, et al. Combination of a Novel EP4 Antagonist E7046 and Radiation Therapy Promotes Anti-tumor Immune Response and Tumor Rejection in Preclinical Tumor Models. International Journal of Radiation Oncology Biology Physics
2. Diana I. Albu, et al. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity. OncoImmunology.
molnova catalog
related products
-
AM211
AM211 is a potent and orally bioavailable antagonist of prostaglandin D2 (PGD2) receptor type 2 (DP2).
-
MF-766
MF-766 is a highly potent, selective and orally active EP4 antagonist with a Ki of 0.23 nM. It behaves as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay. It can be used for cancer and inflammation diseases research.
-
Bupivacaine hydrochl...
Bupivacaine hydrochloride binds to the intracellular portion of voltage-gated sodium channels and blocks sodium influx into nerve cells.
